ChromaDex (NASDAQ:CDXC) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of ChromaDex (NASDAQ:CDXC) in a research report sent to investors on Saturday morning. The brokerage issued a buy rating on the stock.

CDXC has been the subject of several other research reports. LADENBURG THALM/SH SH raised their price target on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of ChromaDex in a research report on Monday, March 17th.

ChromaDex Stock Performance

ChromaDex has a 1 year low of $2.31 and a 1 year high of $9.18. The firm’s fifty day moving average is $6.16 and its 200-day moving average is $5.44. The company has a market capitalization of $611.50 million, a price-to-earnings ratio of 787.29 and a beta of 2.21.

Institutional Trading of ChromaDex

Institutional investors have recently modified their holdings of the business. USA Financial Formulas purchased a new stake in ChromaDex during the 4th quarter worth about $25,000. State of Wyoming purchased a new stake in shares of ChromaDex in the fourth quarter worth about $39,000. Mercer Global Advisors Inc. ADV bought a new position in shares of ChromaDex in the fourth quarter valued at approximately $53,000. Truist Financial Corp purchased a new position in ChromaDex during the fourth quarter valued at approximately $54,000. Finally, FMR LLC bought a new stake in ChromaDex during the 3rd quarter worth approximately $55,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.